Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Receivables - Doubtful: 2013-2016

  • RedHill Biopharma's Receivables - Doubtful fell 79.01% to $1.2 million in Q4 2016 from the same period last year, while for Dec 2016 it was $1.2 million, marking a year-over-year decrease of 79.01%. This contributed to the annual value of $1.2 million for FY2016, which is 79.01% down from last year.
  • RedHill Biopharma's Receivables - Doubtful amounted to $1.2 million in Q4 2016, which was down 79.01% from $5.9 million recorded in Q4 2015.
  • RedHill Biopharma's 5-year Receivables - Doubtful high stood at $16.8 million for Q4 2013, and its period low was $1.2 million during Q4 2016.
  • Moreover, its 3-year median value for Receivables - Doubtful was $5.9 million (2015), whereas its average is $6.3 million.
  • Data for RedHill Biopharma's Receivables - Doubtful shows a maximum YoY tumbled of 79.01% (in 2016) over the last 5 years.
  • Quarterly analysis of 4 years shows RedHill Biopharma's Receivables - Doubtful stood at $16.8 million in 2013, then declined by 29.52% to $11.9 million in 2014, then crashed by 50.28% to $5.9 million in 2015, then tumbled by 79.01% to $1.2 million in 2016.
  • Its Receivables - Doubtful stands at $1.2 million for Q4 2016, versus $5.9 million for Q4 2015 and $11.9 million for Q4 2014.